Abstract: Objective: The objective is to assess the performance of the 2023 American College of Rheumatology/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) in a Mexican cohort.
Methods: We enrolled patients with primary APS (PAPS) and secondary APS (SAPS) and a control group of nonautoimmune thrombophilia. We evaluated the fulfillment of the 2023 AECC and the 2006 revised Sapporo classification criteria (2006 RSCC) and their performance against the clinical diagnosis as the gold standard. The baseline Global APS Score (GAPSS) and the Damage Index for APS (DIAPS) at last follow-up were calculated.
Results: We included 85 patients with PAPS, 54 with SAPS, and 50 with thrombophilia. According to the 2023 AECC criteria, 69 patients (81.2%) with PAPS, 28 patients (51.9%) with SAPS, and none of the patients with thrombophilia met the criteria. When comparing true positive (TP) (n = 69) versus false negative (n = 16) cases within the PAPS group, TP cases exhibited a higher frequency of thrombotic manifestations and IgM anti-cardiolipin and IgG anti-β2-glycoprotein-I positivity. For PAPS, there was a correlation between the 2023 AECC score and both GAPSS (rho = 0.621, P < 0.0001) and DIAPS scores (rho = 0.433, P < 0.0001). When comparing the 2023 AECC with the 2006 RSCC, a lower sensitivity (81.2% vs 88.2%) but a higher specificity (100.0% vs 92.0%) was observed for PAPS. Similar findings were observed in SAPS.
Conclusion: In both PAPS and SAPS, the 2023 AECC have higher specificity than the 2006 RSCC. The main feature of patients with PAPS according to the 2023 AECC was thrombosis. These criteria might identify patients at higher risk of thrombosis and damage accrual.
(© 2024 American College of Rheumatology.)
References: Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ 2023;380:e069717.
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42(7):1309–1311.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4(2):295–306.
Barbhaiya M, Zuily S, Naden R, et al; ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023;75(10):1687–1702.
Barbhaiya M, Taghavi M, Zuily S, et al; New APS Classification Criteria Steering Committee and APS ACTION Collaborators. Efforts to better characterize “antiphospholipid antibody nephropathy” for the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report. J Rheumatol 2024;51(2):150–159.
Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti‐Phospholipid Syndrome Score. Rheumatology (Oxford) 2013;52(8):1397–1403.
Amigo MC, Goycochea‐Robles MV, Espinosa‐Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus 2015;24(9):927–934.
Tang Z, Shi H, Liu HL, et al. Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’. Ann Rheum Dis 2024;83(3):e4.
Lu Q, Gan Y, Yao Z, et al. A diagnostic performance study of the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for patients with antiphospholipid syndrome from the Antiphospholipid Syndrome Chinese Collaborative cohort presenting with suspected antiphospholipid syndrome. Arthritis Rheumatol 2024;76:1317–1318.
Zhao Y, Huang C, Zhou Y, et al. Performance validation of the 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria in an antiphospholipid syndrome cohort. J Thromb Haemost 2024:22(6):1660–1674.
Miro‐Mur FA, Alijotas‐Reig J, Anunciacion‐Llunell A, et al. Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’. Ann Rheum Dis 2024;83(3):e2.
Foddai SG, Radin M, Cecchi I, et al. 2023 ACR/EULAR classification criteria in existing research cohorts: an international study. Rheumatology (Oxford) 2024;2024:keae058.
Huisman A, Urbanus RT, Meijer P. Antiphospholipid antibody solid phase‐based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome. J Thromb Haemost 2024;22(3):874–876.
Whittall‐Garcia L, Gladman DD, Urowitz MB, et al. The new EULAR/ACR 2019 SLE classification criteria: a predictor of long‐term outcomes. Semin Arthritis Rheum 2022;57:152103.
Processing Request
No Comments.